Estimated undertreatment of carbapenem-resistant Gram-negative bacterial infections in eight low-income and middle-income countries: a modelling study
Over the past quarter century, antimicrobial resistance (AMR) has emerged as a major global health threat. It is estimated that almost 1·1 million deaths annually are a direct result of AMR—more than the combined deaths from HIV/AIDS and malaria in 2022.1–3 Overwhelmingly, low-income and middle-income countries (LMICs) bear this burden—nearly 90% of AMR-related deaths each year are estimated to occur in LMICs. Today, a child born in Africa is 58 times more likely to die from a drug-resistant infection in the first 5 years of life than one born in a high-income country. With bacterial drug resistance rates continuing to increase, and without concerted action, almost 40 million cumulative deaths are projected by 2050.
Authors:
Anant Mishra, Rahul Dwivedi, Kim Faure, Prof Daniel J Morgan, Jennifer Cohn